My ePortfolio Register   

SABCS 2016 /
A phase III study of buparlisib and fulvestrant in HR positive advanced breast cancer

6th - 10th Dec 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.12.16
Views: 1187

Dr Ruth O'Regan - University of Wisconsin-Madison, Madison, USA

Dr O'Regan presents data at the 2016 San Antonio Breast Cancer Symposium from the BELLE-3 trial of buparlisib and fulvestrant for post-menopausal women with locally advanced or metastatic breast cancer who have progressed after mTOR inhibitory therapy.

With a primary endpoint of improved progression-free survival, and secondary endpoints of assessing risk through PIK3CA expression, she describes this trial as a success, but notes a slight incidence of psychological effects on a minority of patients, which may be due to the small size of buparlisib permitting it to cross the blood brain barrier.

She discusses these results further in her interview with ecancer, here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence